Abstract
Imidapril is an angiotensin-converting enzyme inhibitor that is widely used in treating hypertension, although the responses vary among individuals. We investigated whether a single nucleotide polymorphism at position −816 of the carboxylesterase 1 (CES1) gene, which activates imidapril in the liver, is involved in the responsiveness to imidapril medication. A total of 105 Japanese hypertensives with systolic/diastolic blood pressures (SBP/DBP) of 140/90 mmHg or higher were prescribed 5–10 mg/day of imidapril. At baseline, blood pressure levels were not different between patients with and those without the −816C allele (AA vs. AC+CC groups). After 8 weeks of treatment, we classified the responders and non-responders based on the decline in their blood pressures, and found that the responder rate was significantly higher in the AC+CC group than in the AA group (p=0.0331). Also, the reduction in SBP was significantly greater in the AC+CC group than in the AA group (24.7±11.8 vs. 17.6±16.8 mmHg, p=0.0184). Furthermore, an in vitro reporter assay revealed that the −816C construct had significantly higher promoter activity (p<0.0001). These findings suggest that the A(−816)C polymorphism affects the transcriptional activity, and that this may account for the responsiveness to imidapril.
Similar content being viewed by others
Article PDF
References
Kato N : Genetic analysis in human hypertension. Hypertens Res 2002; 25: 319–327.
World Health Organization (WHO)/International Society of Hypertension (ISH) : 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.
Johnston CI, Risvanis J : Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. Am J Hypertens 1997; 10: 306S–310S.
Unger T : The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A–10A.
Baudin B : Angiotensin I-converting enzyme gene polymorphism and drug response. Clin Chem Lab Med 2000; 38: 853–856.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F : An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343–1346.
Tamaki S, Nakamura Y, Tsujita Y, et al: Polymorphism of the angiotensin converting enzyme gene and blood pressure in a Japanese general population (the Shigaraki Study). Hypertens Res 2002; 25: 843–848.
Li X, Du Y, Huang X : Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol Ther 2003; 8: 25–30.
Stavroulakis GA, Makris TK, Krespi PG, et al: Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovasc Drugs Ther 2000; 14: 427–432.
Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ : Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 1995; 13: 1602–1609.
Mondorf UF, Russ A, Wiesemann A, Herrero M, Oremek G, Lenz T : Contribution of angiotensin I converting enzyme gene polymorphism and angiotensinogen gene polymorphism to blood pressure regulation in essential hypertension. Am J Hypertens 1998; 11: 174–183.
Katsuya T, Iwashima Y, Sugimoto K, et al: Effects of antihypertensive drugs and gene variants in the renin-angiotensin system. Hypertens Res 2001; 24: 463–467.
Huang PJ, Chien KL, Chen MF, Lai LP, Chiang FT : Efficacy and safety of imidapril in patients with essential hypertension: a double-blind comparison with captopril. Cardiology 2001; 95: 146–150.
van der Does R, Euler R : A randomized, double-blind, parallel-group study to compare the anti-hypertensive effects of imidapril and nifedipine in the treatment of mild-to-moderate essential hypertension. J Int Med Res 2001; 29: 154–162.
Zweiker R, Stoschitzky K, Maier R, Klein W : Efficiency and safety of ACE-inhibiting imidapril in patients with essential hypertension. Acta Med Austriaca 2002; 29: 72–76.
Okamura A, Ohishi M, Rakugi H, et al: Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 1999; 50: 811–822.
Yu H, Zhang Y, Liu G : Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens Res 2003; 26: 881–886.
Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN : Current progress on esterases: from molecular structure to function. Drug Metab Dispos 2002; 30: 488–493.
Song JC, White CM : Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41: 207–224.
Takai S, Matsuda A, Usami Y, et al: Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 1997; 20: 869–873.
Livak KJ : Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14: 143–149.
Becker A, Bottcher A, Lackner KJ, et al: Purification, cloning, and expression of a human enzyme with acyl coenzyme A: cholesterol acyltransferase activity, which is identical to liver carboxylesterase. Arterioscler Thromb 1994; 14: 1346–1355.
Munger JS, Shi GP, Mark EA, Chin DT, Gerard C, Chapman HA : A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J Biol Chem 1991; 266: 18832–18838.
Kroetz DL, McBride OW, Gonzalez FJ : Glycosylation-dependent activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. Biochemistry 1993; 32: 11606–11617.
Ghosh S : Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA. Physiol Genomics 2000; 2: 1–8.
Shibata F, Takagi Y, Kitajima M, Kuroda T, Omura T : Molecular cloning and characterization of a human carboxylesterase gene. Genomics 1993; 17: 76–82.
Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF : Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos 2004; 32: 505–511.
Ghosh S, Natarajan R : Cloning of the human cholesteryl ester hydrolase promoter: identification of functional peroxisomal proliferator-activated receptor responsive elements. Biochem Biophys Res Commun 2001; 284: 1065–1070.
Saito S, Iida A, Sekine A, et al: Catalog of 680 variations among eight cytochrome p450 (CYP) genes, nine esterase genes, and two other genes in the Japanese population. J Hum Genet 2003; 48: 249–270.
Yokoyama C, Wang X, Briggs MR, et al: SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 1993; 75: 187–197.
Smith JR, Osborne TF, Goldstein JL, Brown MS : Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J Biol Chem 1990; 265: 2306–2310.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Geshi, E., Kimura, T., Yoshimura, M. et al. A Single Nucleotide Polymorphism in the Carboxylesterase Gene Is Associated with the Responsiveness to Imidapril Medication and the Promoter Activity. Hypertens Res 28, 719–725 (2005). https://doi.org/10.1291/hypres.28.719
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.719
Keywords
This article is cited by
-
Carboxylesterases in lipid metabolism: from mouse to human
Protein & Cell (2018)
-
CES1 genetic variation affects the activation of angiotensin-converting enzyme inhibitors
The Pharmacogenomics Journal (2016)
-
Regulations of Xenobiotics and Endobiotics on Carboxylesterases: A Comprehensive Review
European Journal of Drug Metabolism and Pharmacokinetics (2016)
-
CES1P1 variant −816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril
European Journal of Clinical Pharmacology (2016)
-
Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
Clinical Pharmacokinetics (2015)